{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:15:21Z","timestamp":1792671321068,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.metabol.2012.07.024","type":"journal-article","created":{"date-parts":[[2012,10,4]],"date-time":"2012-10-04T19:46:25Z","timestamp":1349379985000},"page":"479-491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":150,"title":["Lipoprotein(a) metabolism: Potential sites for therapeutic targets"],"prefix":"10.1016","volume":"62","author":[{"given":"Jane","family":"Hoover-Plow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menggui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2012.07.024_bb0005","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2014the Lp system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"key":"10.1016\/j.metabol.2012.07.024_bb0010","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0015","first-page":"1673","article-title":"Instability of lipoprotein(a) in plasma stored at \u221270 degrees C: effects of concentration, apolipoprotein(a) genotype, and donor cardiovascular disease","volume":"47","author":"Simo","year":"2001","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0020","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2012.07.024_bb0025","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2012.07.024_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2009.12.036","article-title":"Lipoprotein(a) and ischemic heart disease\u2014a causal association? A review","volume":"211","author":"Kamstrup","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2012.07.024_bb0035","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2012.07.024_bb0040","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0038-1645041","article-title":"Lp(a): an interloper into the fibrinolytic system?","volume":"63","author":"Miles","year":"1990","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.metabol.2012.07.024_bb0045","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2012.07.024_bb0060","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1517\/13543784.2011.548804","article-title":"Sex hormones and lipoprotein(a) concentration","volume":"20","author":"Gaeta","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.metabol.2012.07.024_bb0570","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2174\/157016111797484071","article-title":"Lipoprotein(a): current perspectives","volume":"9","author":"Gouni-Berthold","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0585","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/3-540-27661-0_19","article-title":"Therapy of hyper-Lp(a)","author":"Kostner","year":"2005","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0070","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1172\/JCI45277","article-title":"Farnesoid X receptor represses hepatic human APOA gene expression","volume":"121","author":"Chennamsetty","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2012.07.024_bb0165","doi-asserted-by":"crossref","first-page":"G543","DOI":"10.1152\/ajpgi.90585.2008","article-title":"A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia","volume":"296","author":"Evans","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0170","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.111.243055","article-title":"FGF19 signaling cascade suppresses APOA gene expression","author":"Chennamsetty","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0255","first-page":"69","article-title":"Lipoprotein(a): biology and clinical importance","volume":"25","author":"McCormick","year":"2004","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.metabol.2012.07.024_bb0265","doi-asserted-by":"crossref","first-page":"13681","DOI":"10.1021\/bi00212a037","article-title":"Comparison of the lysine binding functions of lipoprotein(a) and plasminogen","volume":"32","author":"Hoover-Plow","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.metabol.2012.07.024_bb0270","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1388-1981(99)00044-X","article-title":"Effect of tranexamic acid and delta-aminovaleric acid on lipoprotein(a) metabolism in transgenic mice","volume":"1438","author":"Frank","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2012.07.024_bb0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/vhrm.2006.2.1.87","article-title":"Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in Asian Indian dyslipidemic patients: a multicentric study","volume":"2","author":"Sharma","year":"2006","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.metabol.2012.07.024_bb0575","first-page":"31","article-title":"Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin","volume":"5","author":"Robinson","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.metabol.2012.07.024_bb0580","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1194\/jlr.M008961","article-title":"Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy","volume":"51","author":"Nicholls","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2012.07.024_bb0590","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/MJT.0b013e3181e00bf1","article-title":"Lipoprotein(a): from molecules to therapeutics","volume":"17","author":"Bermudez","year":"2010","journal-title":"Am J Ther"},{"key":"10.1016\/j.metabol.2012.07.024_bb0330","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0905633","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia","volume":"362","author":"Ladenson","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2012.07.024_bb0605","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0050","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2012.07.024_bb0065","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/sj.ki.5002131","article-title":"In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients","volume":"71","author":"Frischmann","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2012.07.024_bb0075","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI117292","article-title":"The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate","volume":"93","author":"Rader","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2012.07.024_bb0080","first-page":"151","article-title":"Metabolism of lipoprotein Lp(a)","volume":"8","author":"Krempler","year":"1980","journal-title":"Artery"},{"key":"10.1016\/j.metabol.2012.07.024_bb0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11745-999-0370-z","article-title":"Lipoprotein (a) metabolism estimated by nonsteady-state kinetics","volume":"34","author":"Parhofer","year":"1999","journal-title":"Lipids"},{"key":"10.1016\/j.metabol.2012.07.024_bb0090","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2012.07.024_bb0095","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.ATV.15.3.385","article-title":"Effect of glycation on the properties of lipoprotein(a)","volume":"15","author":"Makino","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0005-2760(98)00022-8","article-title":"Enzymatic and chemical modifications of lipoprotein(a) selectively alter its lysine-binding functions","volume":"1392","author":"Hoover-Plow","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2012.07.024_bb0105","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jacc.2010.04.048","article-title":"Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events","volume":"56","author":"Tsimikas","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0110","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1161\/01.ATV.11.4.1030","article-title":"Lipoprotein(a) and apolipoprotein(a) in a New World monkey, the common marmoset (Callithrix jacchus). Association of variable plasma lipoprotein(a) levels with a single apolipoprotein(a) isoform","volume":"11","author":"Guo","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.metabol.2012.07.024_bb0115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0005-2760(89)90180-X","article-title":"Seasonal variations of plasma lipids and lipoproteins in the hedgehog, an animal model for lipoprotein (a) metabolism: relation to plasma thyroxine and testosterone levels","volume":"1005","author":"Laplaud","year":"1989","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2012.07.024_bb0120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0021-9150(01)00443-9","article-title":"Gene expression of apolipoprotein(a) within the wall of human aorta and carotid arteries","volume":"158","author":"Fu","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2012.07.024_bb0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0021-9150(91)90187-8","article-title":"Detection and quantitation of apolipoprotein(a) mRNA in human liver and its relationship with plasma lipoprotein(a) concentration","volume":"91","author":"Wade","year":"1991","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2012.07.024_bb0180","doi-asserted-by":"crossref","first-page":"e14328","DOI":"10.1371\/journal.pone.0014328","article-title":"Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases","volume":"5","author":"Schultz","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2012.07.024_bb0130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2008.01.002","article-title":"The apolipoprotein(a) gene: linkage disequilibria at three loci differs in African Americans and Caucasians","volume":"201","author":"Rubin","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2012.07.024_bb0135","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0015-0282(01)01699-5","article-title":"Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974\u20132000","volume":"75","author":"Godsland","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2012.07.024_bb0140","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/01.CIR.87.4.1135","article-title":"Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study","volume":"87","author":"Jenner","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2012.07.024_bb0145","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1161\/01.ATV.17.9.1741","article-title":"Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice","volume":"17","author":"Zysow","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0150","doi-asserted-by":"crossref","first-page":"15569","DOI":"10.1074\/jbc.274.22.15569","article-title":"Estrogen modulation of apolipoprotein(a) expression. Identification of a regulatory element","volume":"274","author":"Boffelli","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0155","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1073\/pnas.90.4.1369","article-title":"5' control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family","volume":"90","author":"Wade","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2012.07.024_bb0160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1042\/bj20030985","article-title":"A proximal tissue-specific module and a distal negative regulatory module control apolipoprotein(a) gene transcription","volume":"379","author":"Negi","year":"2004","journal-title":"Biochem J"},{"key":"10.1016\/j.metabol.2012.07.024_bb0175","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/01.ATV.18.6.984","article-title":"Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures","volume":"18","author":"Ramharack","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0185","doi-asserted-by":"crossref","first-page":"e24719","DOI":"10.1371\/journal.pone.0024719","article-title":"Association between the interleukin-6 promoter polymorphism -174G\/C and serum lipoprotein(a) concentrations in humans","volume":"6","author":"Berthold","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2012.07.024_bb0190","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1074\/jbc.273.2.891","article-title":"Apolipoprotein(a) gene enhancer resides within a LINE element","volume":"273","author":"Yang","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0195","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0021-9150(02)00315-5","article-title":"Sequence and functional changes in a putative enhancer region upstream of the apolipoprotein(a) gene","volume":"166","author":"Puckey","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2012.07.024_bb0200","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1161\/01.ATV.0000084637.01883.CA","article-title":"Regulation of the expression of the apolipoprotein(a) gene: evidence for a regulatory role of the 5' distal apolipoprotein(a) transcription control region enhancer in yeast artificial chromosome transgenic mice","volume":"23","author":"Huby","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0205","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1042\/bst0270453","article-title":"Role of N-linked glycans, chaperone interactions and proteasomes in the intracellular targeting of apolipoprotein(a)","volume":"27","author":"Wang","year":"1999","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.metabol.2012.07.024_bb0210","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0009-3084(94)90132-5","article-title":"Oleate stimulates the formation of triglyceride-rich particles containing apoB100-apo(a) in long-term primary cultures of human hepatocytes","volume":"67\u201368","author":"Edelstein","year":"1994","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.metabol.2012.07.024_bb0215","doi-asserted-by":"crossref","first-page":"17793","DOI":"10.1074\/jbc.273.28.17793","article-title":"Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion","volume":"273","author":"Nassir","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0220","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1074\/jbc.272.9.5659","article-title":"Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a)","volume":"272","author":"Bonen","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0225","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0009-3084(94)90131-7","article-title":"Intracellular processing of apo(a) in primary baboon hepatocytes","volume":"67\u201368","author":"White","year":"1994","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.metabol.2012.07.024_bb0230","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1021\/bi972761t","article-title":"Intracellular metabolism of human apolipoprotein(a) in stably transfected Hep G2 cells","volume":"37","author":"Lobentanz","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.metabol.2012.07.024_bb0235","doi-asserted-by":"crossref","first-page":"24369","DOI":"10.1016\/S0021-9258(18)35775-2","article-title":"Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a)","volume":"267","author":"Chiesa","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0240","first-page":"3267","article-title":"Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement","volume":"83","author":"Su","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2012.07.024_bb0245","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0021-9150(00)00732-2","article-title":"The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans","volume":"157","author":"Demant","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2012.07.024_bb0250","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.metabol.2004.10.001","article-title":"The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings","volume":"54","author":"Jenner","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2012.07.024_bb0260","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1161\/01.ATV.15.10.1774","article-title":"Inhibitors for the in vitro assembly of Lp(a)","volume":"15","author":"Frank","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0275","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1194\/jlr.M400163-JLR200","article-title":"Structural features of apolipoprotein B synthetic peptides that inhibit lipoprotein(a) assembly","volume":"45","author":"Sharp","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2012.07.024_bb0280","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.gt.3301434","article-title":"Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo","volume":"8","author":"Frank","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.metabol.2012.07.024_bb0285","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","article-title":"Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice","volume":"118","author":"Merki","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2012.07.024_bb0290","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI114602","article-title":"Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice","volume":"85","author":"Hofmann","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2012.07.024_bb0295","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/01.ATV.20.2.522","article-title":"Lipoprotein(a) in homozygous familial hypercholesterolemia","volume":"20","author":"Kraft","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0300","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0009-3084(94)90142-2","article-title":"Lp(a) catabolism in hypercholesterolaemic individuals","volume":"67\u201368","author":"Knight","year":"1994","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.metabol.2012.07.024_bb0305","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0022-2275(20)37140-6","article-title":"Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein","volume":"38","author":"Reblin","year":"1997","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2012.07.024_bb0310","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.ATV.19.3.552","article-title":"Identification of megalin\/gp330 as a receptor for lipoprotein(a) in vitro","volume":"19","author":"Niemeier","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0315","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1172\/JCI119753","article-title":"The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor","volume":"100","author":"Argraves","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2012.07.024_bb0320","doi-asserted-by":"crossref","first-page":"10825","DOI":"10.1016\/S0021-9258(18)99093-9","article-title":"Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen","volume":"266","author":"Kanalas","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0325","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/105072503321669857","article-title":"Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine","volume":"13","author":"Milionis","year":"2003","journal-title":"Thyroid"},{"key":"10.1016\/j.metabol.2012.07.024_bb0335","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/s-0038-1653797","article-title":"Interaction of Lp(a) with plasminogen binding sites on cells","volume":"73","author":"Miles","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.metabol.2012.07.024_bb0340","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1074\/jbc.270.11.6227","article-title":"Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32\u201336 of human apolipoprotein(a)","volume":"270","author":"Ernst","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0345","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/141806","article-title":"So many plasminogen receptors: why?","author":"Plow","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0350","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tcm.2010.10.002","article-title":"Plasminogen and its receptors as regulators of cardiovascular inflammatory responses","volume":"20","author":"Das","year":"2010","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.metabol.2012.07.024_bb0355","doi-asserted-by":"crossref","first-page":"5622","DOI":"10.1182\/blood-2011-03-344242","article-title":"Regulation of macrophage migration by a novel plasminogen receptor Plg-R KT","volume":"118","author":"Lighvani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.metabol.2012.07.024_bb0360","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/clinchem\/38.11.2244","article-title":"Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure","volume":"38","author":"Oida","year":"1992","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0365","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1172\/JCI118487","article-title":"Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a)","volume":"97","author":"Mooser","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2012.07.024_bb0370","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/01.ATV.16.8.905","article-title":"Urinary excretion of apo(a) fragments. Role in apo(a) catabolism","volume":"16","author":"Kostner","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0375","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1365-2362.2001.00811.x","article-title":"Role of various tissues in apo(a) fragmentation and excretion of fragments by the kidney","volume":"31","author":"Frank","year":"2001","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.metabol.2012.07.024_bb0380","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0009-8981(00)00394-6","article-title":"Urinary excretion of apolipoprotein(a): relation to other plasma proteins","volume":"304","author":"Kostner","year":"2001","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.metabol.2012.07.024_bb0385","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1161\/hq0801.093654","article-title":"Molecular analysis of apo(a) fragmentation in polygenic hypercholesterolemia: characterization of a new plasma fragment pattern","volume":"21","author":"Gonbert","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0390","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/07853899809002492","article-title":"Urinary apolipoprotein (a) excretion in patients with proteinuria","volume":"30","author":"Kostner","year":"1998","journal-title":"Ann Med"},{"key":"10.1016\/j.metabol.2012.07.024_bb0395","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/ajkd.2001.26889","article-title":"Renal handling of human apolipoprotein(a) and its fragments in the rat","volume":"38","author":"Reblin","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.metabol.2012.07.024_bb0400","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1042\/bj20030932","article-title":"Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism","volume":"376","author":"Hrzenjak","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.metabol.2012.07.024_bb0405","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1194\/jlr.M500249-JLR200","article-title":"Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]","volume":"46","author":"Cain","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2012.07.024_bb0410","doi-asserted-by":"crossref","first-page":"11079","DOI":"10.1074\/jbc.272.17.11079","article-title":"Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments","volume":"272","author":"Edelstein","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0415","doi-asserted-by":"crossref","first-page":"10019","DOI":"10.1074\/jbc.274.15.10019","article-title":"Macrophage metalloelastase, MMP-12, cleaves human apolipoprotein(a) in the linker region between kringles IV-4 and IV-5. Potential relevance to lipoprotein(a) biology","volume":"274","author":"Edelstein","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0420","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1067\/mva.2000.107757","article-title":"Apolipoprotein (a) fragments in relation to human carotid plaque instability","volume":"32","author":"Fortunato","year":"2000","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.metabol.2012.07.024_bb0425","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0022-2275(20)39699-1","article-title":"Partial characterization of lipoproteins containing apo[a] in human atherosclerotic lesions","volume":"34","author":"Hoff","year":"1993","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2012.07.024_bb0430","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1172\/JCI118824","article-title":"Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesioned rabbit aorta","volume":"98","author":"Nielsen","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2012.07.024_bb0435","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0268-9499(98)80380-9","article-title":"Interaction of lipoprotein(a) with the extracellular matrix","volume":"12","author":"Miles","year":"1997","journal-title":"Fibrinolysis Proteolysis"},{"key":"10.1016\/j.metabol.2012.07.024_bb0440","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1055\/s-0037-1616056","article-title":"The Kringle V-protease domain is a fibrinogen binding region within Apo(a)","volume":"86","author":"Xue","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.metabol.2012.07.024_bb0445","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1050-1738(00)00020-7","article-title":"Dominant role of the C-terminal domain in the binding of apolipoprotein(a) to the protein core of proteoglycans and other members of the vascular matrix","volume":"9","author":"Scanu","year":"1999","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.metabol.2012.07.024_bb0450","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1055\/s-0037-1614960","article-title":"Phospholipase A2 modification enhances lipoprotein(a) binding to the subendothelial matrix","volume":"79","author":"Hoover-Plow","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.metabol.2012.07.024_bb0455","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1194\/jlr.M500239-JLR200","article-title":"Elements in the C terminus of apolipoprotein [a] responsible for the binding to the tenth type III module of human fibronectin","volume":"46","author":"Edelstein","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2012.07.024_bb0460","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00438-002-0673-6","article-title":"Direct interaction of the extracellular matrix protein DANCE with apolipoprotein(a) mediated by the kringle IV-type 2 domain","volume":"267","author":"Kapetanopoulos","year":"2002","journal-title":"Mol Genet Genomics"},{"key":"10.1016\/j.metabol.2012.07.024_bb0465","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1538-7836.2006.01946.x","article-title":"Elusive proatherothrombotic role of Lp(a): a new direction?","volume":"4","author":"Hoover-Plow","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.metabol.2012.07.024_bb0470","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1172\/JCI119671","article-title":"Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus","volume":"100","author":"Hughes","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2012.07.024_bb0475","doi-asserted-by":"crossref","first-page":"12591","DOI":"10.1073\/pnas.95.21.12591","article-title":"Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice","volume":"95","author":"Lou","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2012.07.024_bb0480","first-page":"2007","article-title":"Defensin promotes the binding of lipoprotein(a) to vascular matrix","volume":"94","author":"Bdeir","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.metabol.2012.07.024_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbalip.2004.10.005","article-title":"The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin: contribution to selective retention of lipoprotein(a) in atherosclerotic lesions","volume":"1687","author":"D'Angelo","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2012.07.024_bb0490","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1476-511X-10-174","article-title":"The relationship between oxidized lipoprotein(a) and carotid atherosclerosis in asymptomatic subjects: a comparison with native lipoprotein(a)","volume":"10","author":"Kotani","year":"2011","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.metabol.2012.07.024_bb0495","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.atherosclerosis.2010.10.048","article-title":"Differential expression of oxidized\/native lipoprotein(a) and plasminogen in human carotid and cerebral artery plaques","volume":"215","author":"Umahara","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2012.07.024_bb0500","doi-asserted-by":"crossref","first-page":"581","DOI":"10.5301\/JN.2011.6442","article-title":"OxPL\/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients","volume":"24","author":"Bossola","year":"2011","journal-title":"J Nephrol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0505","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1016\/S0021-9258(19)50640-8","article-title":"Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages","volume":"267","author":"Haberland","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0510","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0009-3084(94)90136-8","article-title":"Oxidative modification of Lp(a) causes changes in the structure and biological properties of apo(a)","volume":"67\u201368","author":"Naruszewicze","year":"1994","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.metabol.2012.07.024_bb0515","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/0925-4439(94)90076-0","article-title":"Hypochlorite oxidation causes cross-linking of Lp(a)","volume":"1225","author":"O'Connell","year":"1994","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2012.07.024_bb0520","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0038-1656346","article-title":"Lysine-binding heterogeneity of Lp(a): consequences for fibrin binding and inhibition of plasminogen activation","volume":"68","author":"Bas Leerink","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.metabol.2012.07.024_bb0525","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0009-9120(94)90049-3","article-title":"Structure and possible biological roles of Lp(a)","volume":"27","author":"Karmansky","year":"1994","journal-title":"Clin Biochem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0530","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/s-0037-1615598","article-title":"Impact of apolipoprotein(a) isoform size heterogeneity on the lysine binding function of lipoprotein(a) in early onset coronary artery disease","volume":"85","author":"Simo","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.metabol.2012.07.024_bb0535","doi-asserted-by":"crossref","first-page":"31151","DOI":"10.1074\/jbc.270.52.31151","article-title":"Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein","volume":"270","author":"Blencowe","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2012.07.024_bb0540","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1194\/jlr.M400467-JLR200","article-title":"High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins","volume":"46","author":"Schneider","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2012.07.024_bb0545","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrcardio.2011.91","article-title":"Arterial thrombus formation in cardiovascular disease","volume":"8","author":"Lippi","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0550","first-page":"463","article-title":"Lipoprotein(a) and ageing","volume":"56","author":"Lippi","year":"2010","journal-title":"Clin Lab"},{"key":"10.1016\/j.metabol.2012.07.024_bb0555","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1196\/annals.1395.016","article-title":"Comparison of lipoprotein(a) levels between elderly and middle-aged men with coronary artery disease","volume":"1100","author":"Cicek","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.metabol.2012.07.024_bb0560","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.coph.2006.06.009","article-title":"PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome","volume":"6","author":"Fievet","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.metabol.2012.07.024_bb0565","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0022-2275(20)41137-X","article-title":"Gemfibrozil significantly lowers cynomolgus monkey plasma lipoprotein[a]-protein and liver apolipoprotein[a] mRNA levels","volume":"36","author":"Ramharack","year":"1995","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2012.07.024_bb0595","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2012.07.024_bb0600","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/VHRM.S25238","article-title":"Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases","volume":"8","author":"Shinkai","year":"2012","journal-title":"Vasc Health Risk Manag"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049512003332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049512003332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T03:59:32Z","timestamp":1758427172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049512003332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":121,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0026049512003332"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2012.07.024","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) metabolism: Potential sites for therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2012.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}